Status:
COMPLETED
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
Lead Sponsor:
AstraZeneca
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The objective of this study is to determine wether the ZD1839 associated with a radiotherapy, before the beginning of chemotherapy is effective in the treatment of your disease and to evaluate the tol...
Eligibility Criteria
Inclusion
- Signed informed consent.
- 18 to 75 years inclusive.
- At least one measurable lesions histologically confirmed inoperable stage III NSCLC.
- WHO performance status of 0 to 2 inclusive.
- Adequate pulmonary function, pulmonary dose volume histogram less than or equal to 40 %.
- Life expectancy of at least 6 months.
- Using secure contraceptives precautions.
Exclusion
- Any previous anti cancer therapy for NSCLC.
- Known severe hypersensitivity to these products
- Any evidence of clinically active interstitial lung disease
- Other co-existing malignancies, symptomatic metastases.
- Abnormal blood test
- Weight loss of over 15% in the 3 months before the start of the study.
- Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00333294
Start Date
September 1 2004
End Date
January 1 2006
Last Update
December 19 2007
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Clermont-Ferrand, France
2
Research Site
Grenoble, France
3
Research Site
Nantes, France
4
Research SIte
Paris, France